References

This version of the course is no longer available.
Need multiple seats for your university or lab? Get a quote
The page below is a sample from the LabCE course Detection and Management of Preeclampsia: Current Laboratory Testing and Emerging Biomarkers (retired 6/6/2018). Access the complete course and earn ASCLS P.A.C.E.-approved continuing education credits by subscribing online.

Learn more about Detection and Management of Preeclampsia: Current Laboratory Testing and Emerging Biomarkers (retired 6/6/2018) (online CE course)
References

Carty DM, Delles C, Dominiczak AF. Novel biomarkers for predicting preeclampsia. Trends Cardiovasc Med. 2008July;18(5-24):186-194. Available at: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2577131/. Accessed February 5, 2016.
Cause of Preeclampsia. Preeclampsia Foundation website. Available at: http://www.preeclampsia.org/research-top/cause-of-preeclampsia. Accessed February 5, 2016.
Conibere B. Pre-eclampsia: new biomarkers aid in early identification IHE-online, available at: http://www.ihe-online.com/feature-articles/pre-eclampsia-new-biomarkers-aid-in-early-identification/trackback/1/index.html. Accessed February 5, 2016.
Duley L. The global impact of pre-eclampsia and eclampsia. Semin Perinatol. 2009 Jun;33(3):130-137.
Giguere Y, Charland M, Bujold E, et al. Combining biochemical and ultrasonographic markers to predict preeclampsia. Clin Chem. 2010Mar; 56:3:361-375.
Grill S, Rusterholz C, Zanetti-Dällenbach R. Potential markers of preeclampsia -- a review. Reprod Biol Endocrinol. 2009 Jul 14:7:70.
Human VEGF Quantikine® ELISA Kit, R&D Systems, [Product Insert]. Available at: http://www.rndsystems.com/Products/DVE00. Accessed February 5, 2016.
Huppertz B. Meiri H, Gizurarson S, et al. Placental protein 13 (PP13): a new biological target shifting individualized risk assessment to personalized drug design combating pre-eclampsia. Hum Reprod Update. 2013;19(4):391-405.
Lambert-Messerlian GM, Palomaki GE, Neveux LM, et al. Early onset preeclampsia and second trimester serum markers. Prenat Diagn. 2009;29(12):1109-1117. Available at:
Levine RJ, Lam C, Qian C. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med. 2006;355:992-1005.
Lim, KH, Ramus RM. Preeclampsia. Medscape website. Available at: http://emedicine.medscape.com/article/1476919-overview. Accessed February 5, 2015.
Masoura S, Kalogiannidis IA, Gitas G, et al. Biomarkers in pre-eclampsia: a novel approach to early detection of the disease. J Obstet Gynaecol . 2012 Oct;32(7):609-616.
Preeclampsia and Eclampsia. WebMD website. Available at: http://www.webmd.com/baby/guide/preeclampsia-eclampsia. Accessed February 5, 2015.
Preeclampsia risk factors. Mayo Clinic Health Information. Available at http://www.mayoclinic.com/health/preeclampsia/DS00583/DSECTION=risk-factors. Accessed February 5, 2016.
Venkatesha S, Toporsian M, Lam C, Hanai J, et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med. 2006;12:642–9.
Verlohren S, Herraiz I, Lapaire O, et al. The sFlt-1/PlGF ratio in different types of hypertensive pregnancy disorders and its prognostic potential in preeclamptic patients. Am J Obstet Gynecol. 2012 Jan;206(1):58 e1-8.
Zhou, Q, Liu H, Qiao F, et al. VEGF deficit is involved in endothelium dysfunction in preeclampsia. J Huazhong Univ Sci Technolog Med Sci. 2010 Jun;30(3):370-374.